

## Special Issue

# Novel Diagnostic and Therapeutic Approaches to Urologic Oncology

### Message from the Guest Editors

Urologic oncology is one of the most dynamic fields of medicine, with research focused on various fronts, including improvements in developing new tumor markers with increasing roles in early diagnosis and tumor staging. New imaging protocols for prostate cancer and bladder cancer, along with novel chemotherapy regimens and the advancement of targeted and personalized therapies such as immunotherapy and genetic approaches, have led to unprecedented public interest in this field. In this Special Issue, we hope to present the latest discoveries in this field, and welcome submissions that discuss diagnostic or therapeutic strategies in early and advanced urologic oncology, focusing on prostate cancer, bladder cancer, upper urinary tract tumors, renal tumors, testicular or penile cancer, and urethral cancer. You may choose our [Joint Special Issue](#) in *Journal of Clinical Medicine*.

---


### Guest Editors

Dr. Cosmin-Victor Ene  
Prof. Dr. Bogdan Florin Geavlete  
Dr. Cristian I. Surcel

---

### Deadline for manuscript submissions

closed (25 April 2026)



## Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/si/195859](https://mdpi.com/si/195859)

*Journal of Personalized  
Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

[mdpi.com/journal/  
jpm](https://mdpi.com/journal/jpm)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine* is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

---

### Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

---

### Author Benefits

#### High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

#### Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).